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Family planning decisions for parents of children with a rare genetic condition: a 1 
scoping review 2 
Abstract 3 
Expansion of newborn screening programmes increases the complexity around reproductive 4 
choices, both in terms of the increased number of parents faced with making reproductive 5 
decisions from the earliest days of their affected child's life, and the number of conditions for 6 
which such decisions have to be made.  7 
We conducted a scoping review to explore: (i) reproductive decision-making among parents 8 
of children with recessive genetic conditions; and, (ii) the involvement of healthcare services 9 
in facilitating and supporting those decisions. Systematic search processes involved seven 10 
bibliographic databases, citation, and grey literature searches. From an initial total of 311 11 
identified articles, seven met the inclusion criteria and were included in the review.  12 
The extracted data were organised around three themes: factors influencing reproductive 13 
decisions taken by parents, how those factors changed over time, and the involvement of 14 
healthcare services in supporting and facilitating reproductive decisions.  15 
Most studies focused on attitudes towards, and uptake of, pre-natal diagnosis (PND) and 16 
termination. None of the studies considered the wider range of reproductive choices facing all 17 
parents, including those of children with conditions for whom PND and termination is not 18 
available or where good health outcomes make these options less justifiable. The literature 19 
provided little insight into the role of healthcare staff in providing family planning support for 20 
these parents. There is a need to better understand the support parents need in their decision-21 
making, and who is best placed to provide that support. 22 
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Scoping review; recessive genetic conditions; family planning; reproductive decisions; 24 
reproductive services 25 
Abbreviations 26 
CF: Cystic Fibrosis; MCADD: Medium Chain Acyl-CoA dehydrogenase deficiency; NBS: 27 
Newborn bloodspot screening; PIHM: pre-implantation genetic diagnosis; PND: pre-natal 28 
diagnosis; SCD: Sickle Cell Disease; SMA: Spinal Muscular Atrophy29 
2 
 
Introduction  30 
Developments in newborn screening technologies, with Tthe expansion of newborn 31 
bloodspot screening programmes (NBS),  has have brought a substantial increase in the early 32 
detection of rare inherited disorders (1). In the USA, the NBS routinely tests for over thirty 33 
conditions (2), and a similar expansion has occurred in other countries including the 34 
Netherlands, Denmark and Germany (3). In the United Kingdom (UK), more modest 35 
expansions have resulted in the inclusion of six inherited metabolic conditions (Box 1) (4).  36 
 37 
 38 
Screening and early detection of rare conditions enable treatment to be initiated before 39 
significant morbidity has occurred, and can result in substantially improved health outcomes 40 
and reduced likelihood of mortality (5). For example, the benefits of early detection and 41 
active management for phenylketonuria are well established (6), and more recent evidence 42 
indicates the benefits for medium chain Acyl-CoA dehydrogenase deficiency (MCADD) (7-43 
11). The responsibility for managing these conditions, however, rests primarily with parents. 44 
The associated family burden may be substantial (12), although there is some evidence that 45 
this can be mediated by adequate support (13,14). 46 
When a child is diagnosed with a recessive genetic condition, parents need to decide whether 47 
or not to have subsequent children. Their reproductive choices are made within a highly 48 
complex and changing healthcare, social, and technological contexts. Their decisions are 49 
informed by various factors, such as the severity of the condition, and its impact on the child 50 
Box 1: Conditions currently screened by the newborn bloodspot screening 
(NBS) programme in the UK 
(Conditions in bold were included in the database search strategy.) 
sickle cell disease (SCD) 
cystic fibrosis (CF) 
congenital hypothyroidism (CHT) 
inherited metabolic diseases (IMDs): 
phenylketonuria (PKU) 
medium-chain acyl-CoA dehydrogenase deficiency (MCADD) 
maple syrup urine disease (MSUD) 
isovaleric acidaemia (IVA) 
glutaric aciduria type 1 (GA1) 
homocystinuria (HCU) 
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and the family. Furthermore, technological developments make the decision-making process 51 
even more complex. The severity of the condition, and its effect on the child and the family, 52 
are likely to play a key role in parents' decisions. 53 
Another set of factors that may affect the parents' decision  are concerned Their decisions 54 
may also be affected by with the genetic risk (1 in 4) of another affected pregnancy;, and the 55 
availability and acceptability of reproductive technologies including prenatal diagnosis 56 
(PND), or pre-implantation genetic diagnosis (PIGM), to manage that risk; and willingness to 57 
use those technologies.  Advances in non-invasive PND increase the acceptability of these 58 
techniques to parents (15,16), although ethical concerns about their availability and use have 59 
been identified (17). Expansion of the NBS has increased the number of parents faced with 60 
making more complicated reproductive decisions from the earliest days of their affected 61 
child's life, and the number of conditions for which such decisions have to be made. This 62 
indicates the need to understand how parents make decisions about subsequent pregnancies 63 
and the involvement of healthcare services in facilitating and supporting those decisions. 64 
Previous reviews (18,19) have focused on reproductive outcomes in this population but have 65 
not considered reproductive decision-making. In this scoping review we identified and 66 
mapped all studies that explored reproductive decision-making amongst parents of children 67 
with recessive genetic conditions, with respect to the following questions:  68 
 69 
1. What factors influence these decisions? 70 
 71 
2. How do these factors change over time? 72 
 73 
3. What is the involvement of healthcare services in supporting and facilitating these 74 
decisions? 75 
 76 
Methods  77 
We used scoping review methodology (20,21), with robust literature searching and study 78 
selection, coupled with data charting and a thematic narrative summary. We did not formally 79 
assess the quality of included studies.  80 
  81 
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Search strategy 82 
Searches in the following databases were carried out in April 2014 and updated in January 83 
2017: ASSIA (ProQuest), CINAHL Complete (EBSCOHost), HMIC (NICE Evidence 84 
Search), Medline (EBSCOHost), PsycINFO (ProQuest), Scopus (Elsevier), and Web of 85 
Science (Thomson Reuters). 86 
We combined search words/phrases and indexing terms related to autosomal recessive 87 
conditions (named disorders with synonyms, and generic terms) with search words/phrases 88 
and indexing terms related to reproductive decision-making. The named disorders searched 89 
are shown in bold in Box 1. A sensitivity search in Scopus established that none of the 90 
disorders additionally screened for in the US (2) were worth searching for explicitly. 91 
Results were restricted to items published from 2000 onwards, as we were interested in 92 
family planning decision-making within the modern context of an availability of genetic 93 
testing procedures. No language or study design restrictions were applied to the searches, but 94 
non-human studies were removed from the results. An indicative search strategy is provided 95 
in supplementary file 1.  96 
Social Care Online (SCIE) was searched for each disorder of interest separately, screening 97 
the results for relevance to reproductive decision-making. Other websitesGrey literature 98 
sources known to the review team were also searched: see Box 2. searched are shown in Box 99 
2. Reference and citation searches were carried out in respect of included studies. 100 
 101 
Study selection 102 
Inclusion and exclusion criteria were independently applied by two reviewers, with any 103 
disagreements resolved through discussion within the review team. . Papers were included if 104 
Box 2: Websites Grey literature searched 
NHS Evidence search (https://www.evidence.nhs.uk/) - search terms: "family 
planning rare genetic disorder". The first 100 results (ordered by relevance) were 
checked 
The Genetic Alliance UK Website (http://www.geneticalliance.org.uk/  ) - 
browsed for relevant publications 
The Ottawa Hospital Research Institute Website 
(http://204.187.39.28/index.html ) - browsed for relevant decision aids 
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they related to reproductive decision-making by couples who had a child with a recessive 105 
genetic condition and were considering having more children. We excluded papers relating to 106 
couples who did not have an affected child, or papers focusing on: (i) women with a genetic 107 
condition; (ii) the uptake of genetic technologies without exploring the decision-making 108 
process; or (iii) attitudes towards parental screening or (hypothetical) non-invasive prenatal 109 
diagnosis. Included conditions of interest were those shown in bold in Box 1. We excluded 110 
studies relating to autosomal dominant conditions (e.g. Huntingdon's), or other non-genetic 111 
conditions (e.g. hypothyroidism).  112 
We only included studies set in countries whose reproductive health services included well-113 
developed early detection technologies, i.e. Europe, USA, Canada, Australia, and New 114 
Zealand. We included papers that reported any original empirical study, but the reference lists 115 
of retrieved reviews were consulted.  116 
Data extraction and synthesis 117 
We developed a data extraction form for We chartedcharting  the key study characteristics of 118 
the included studies and findings of relevance to our review, which were further thematically 119 
analysed according to our review questions.  120 
Results  121 
Characteristics of included studies 122 
From 311 unique records from the original database searches, plus two further records from 123 
the search update, seven records were included in this review (see Figure 1).  124 
All were peer-reviewed journal articles apart from one conference abstract (22). The main 125 
characteristics of the included studies are provided in Table 1. 126 
Four studies related to reproductive decision-making for parents of children with Cystic 127 
Fibrosis (CF) (23-26), and one each to Sickle Cell Disease (SCD) (22), Spinal Muscular 128 
Atrophy (SMA) (27), and rare metabolic disorders (28). In most of the studies the participants 129 
were recruited from populations using, or known to, health services (22-26,28); one study 130 
recruited predominantly via an advocacy group for the condition (SMA) (27). Four studies 131 
used quantitative (23,24,26,28), and three qualitative research methods (22,25,27).  132 
Most of the studies explored decisions concerning whether to have more children following 133 
the birth of an affected child (22-27), and focused almost exclusively on parental attitudes 134 
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towards use of reproductive technologies to avoid having further affected children. Six of the 135 
studies (22-26,28) focussed on parental attitudes towards PND and termination of affected 136 
pregnancies, with two of these (22,26) also exploring the use of assisted reproductive 137 
technologies such as donor-In Vitro Fertilisation (IVF), and preimplantation genetic 138 
diagnosis (PGD), but provided minimal information about this to inform our review.  139 
In just one study the separate opinions of mothers and fathers in participating couples were 140 
explicitly sought (25). Most studies recruited predominantly mothers (over 87% in three 141 
(22,27,28) and 100% in one (24). One study (23) reported a 'poor response' from fathers in 142 
the baseline survey and only surveyed mothers in the follow-up. The genders of the parent 143 
participants were not reported in one study using data from a national survey (26).  144 
Ethnicity was reported in four of the seven studies. Three included all or mainly white/ 145 
Caucasian participants (24,25,28) and the fourth which focused on SCD included parents of 146 
black or African American origin (22).     147 
 148 
Findings: reproductive decision-making 149 
What factors influence the reproductive decisions taken by parents of a child with a recessive 150 
genetic condition? 151 
In most studies, parental perceptions of coping with their affected child were key to decisions 152 
about having any further children, and decisions about the use of reproductive technologies to 153 
avoid having further affected children. Decisions were based on factors centred both on the 154 
child, and on the parent and their wider family and social network, which. They included 155 
perceptions around their current and future situation, which shifted over time as the parents 156 
adapted to caring for their affected child..  157 
Factors centred on the child included the perceived severity (or otherwise) of the condition 158 
(23,26), concerns about the child's current health (23), worry about the child's future and their 159 
future health (23,28), the (poor) quality of life of the child and the family (23), the potential 160 
impact of another affected child on the existing child and family life, including concern for 161 
increased infection risk (25), and having experienced suffering and death of previous 162 
children(27). In one study, some parents considered their existing child as a role model or 163 
support system for a hypothetical future child having the same condition (22), and in another 164 
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study (23) one mother believed that termination of an affected pregnancy would devalue the 165 
life of their existing child with CF. 166 
Factors centred on the parents included parental stress (28), the impact of caring for the child 167 
on the parents' daily activities (26), the perceived difficulty of meeting the child's care needs 168 
(28), the size of the parents' social support network (28), and the physical strain of caring for 169 
a child with a condition involving a physical disability (27). In one study, the parents' 170 
experience caring for their affected child gave them confidence in their abilities to look after 171 
another child with the same condition (25); indeed, one father was quoted as saying they had 172 
considered adopting another child with CF because of their experiences (25).  173 
Some parents did plan future pregnancies but were prepared to take the risk of having a 174 
further affected child, trusting to chance. In one study (23), some parents believed that the 175 
odds were more likely to be in favour of having a healthy child in the next pregnancy. One 176 
study found that some parents appeared not to make active reproductive choices, but rather 177 
were 'overtaken by events' (25) p.409, which the authors described as a 'decision not to 178 
decide'. Conversely, in another study (26) some parents of children with CF had decided not 179 
to have more children as this was 'easier to decide', obviating potential engagement with 180 
reproductive technologies.  181 
Moral issues were of lesser importance in decision-making: lack of religious conviction was 182 
found to correlate with intention to use PND and consideration of termination (26), and 2/16 183 
mothers cited 'religious reasons' for not terminating a hypothetical affected pregnancy in one 184 
study (23). One study found that for some parents the decision not to have any further 185 
children was driven by a desire not to have any more affected children and unwillingness to 186 
terminate an affected pregnancy (24). 187 
The studies highlight much ambivalence around the use of PND to make decisions about 188 
continuation of pregnancy. Three studies (23,26,28) explored parents' decision making and 189 
reasoning in relation to hypothetical future pregnancies. In one study (26), 13/97 and 26/97 190 
parents of children with CF who were planning more children did not know whether they 191 
would consider terminating or decide to terminate a hypothetical subsequent affected 192 
pregnancy respectively. Two studies (23, 28) found a disjoint between parents wanting to 193 
undergo prenatal diagnosis and their intention to terminate a pregnancy on the basis of that 194 
diagnosis. Among parents of children with CF who had embarked on subsequent pregnancies, 195 
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uptake of PND was largely justified in terms of enabling them to adjust to a positive result, 196 
although all five CF-affected pregnancies had resulted in termination (23).  197 
 198 
How do those factors change over time? 199 
Reproductive decisions may change as the situation of caring for a child with a rare genetic 200 
condition unfolds. This has been explored only with respect to parents of children with CF. In 201 
one study, participants describing their evolving response to having a child with CF (25) 202 
reported that One of the studies invited participants to describe their evolving response to 203 
having a child with CF (25). Participants reported that after the initial shock of diagnosis, 204 
they took some time to adapt and learn how to manage the condition, but once they had 205 
adapted, they felt able to cope and could consider having another child.  206 
As decisions can change over time, hypothetical decisions may not necessarily translate to 207 
actual behaviour. Only one study followed up participants over time to explore this how 208 
hypothetical decisions translated to actual behaviour (23). They found that 16 of the 27 209 
mothers of young children with CF who had at baseline reported not wanting any more 210 
children, had changed their mind at a five-year follow-up. Again, coping was cited as a main 211 
reason for this, along with the child's good health and being more comfortable with the 212 
diagnosis. Conversely, four of the six mothers who originally wanted more children had 213 
changed their mind due to concerns over the child's health. Overall, the study found that in 214 
67% of mothers, the hypothetically reported behaviour regarding the use of PND was the 215 
same as the actual behaviour, but 'mothers not uncommonly changed their minds, and in both 216 
directions' (23) (pe654).  217 
What is the involvement of healthcare services in supporting and facilitating these decisions? 218 
Four studies (23-25, 28) considered the role of healthcare services and all confined their 219 
attention to genetic counselling services and their availability, uptake and acceptability. Some 220 
of the studies reported that some or all the participants had received genetic counselling, 221 
mostly by specialist genetic counselling services (23-25); in the study of reproductive 222 
decisions of parents of children with metabolic disorders (28), the author provided a 223 
breakdown of professional groups which provided genetic counselling, and less than 4% of 224 
genetic counselling was provided by a specialist genetic counsellor either within or outside 225 
the metabolic centre. One study (23) reported that 72% of mothers had rated consultations 226 
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with genetic counsellors as 'extremely useful' or 'very useful'. Other than reporting the 227 
availability and uptake of genetic counselling services, however, the studies did not explore 228 
the role of these or other services in supporting and facilitating reproductive decisions.  229 
Discussion  230 
We found a dearth of recent studies exploring reproductive decision-making of parents of 231 
children with recessive genetic conditions, as previously highlighted (29); the collective 232 
scope of the studies was narrow. Only a small number of conditions were considered, with 233 
the majority focusing on CF, whose findings will have limited applicability to other 234 
conditions. Most studies focused on attitudes towards, and uptake of, PND and termination. 235 
None of the studies considered the wider range of reproductive choices facing all parents 236 
(including those of children with conditions for whom PND and termination is not available 237 
or where good health outcomes make these options less justifiable), and the extent to which 238 
those choices are facilitated. With regard to familial relationships, only one of our included 239 
studies (25) explored the role of both mothers and fathers in couples' reproductive decision-240 
making; for most of the others, mothers were the focus. More generally, this literature base 241 
failed to recognise that reproductive decisions take place in a wider social arena that extends 242 
beyond the confines of PND (30). , and outside the confines of consideration of, and 243 
engagement with, PND. 244 
The reviewed literature did reveal a number of factors which seem to affect reproductive 245 
decisions for this particular population and their relative importance. Many of those revolved 246 
around parental perceptions of coping, now and in the future, with some parents using 247 
scenario-based thinking as a decision-making strategy (25). Moral and religious 248 
considerations seemed to be less significant which is consistent with findings from Atkin et al. 249 
(301).  250 
In presenting factors which may be important in reproductive decision-making, it is important 251 
to recognise the complex interplay between them (25), and the ways in which parents manage 252 
the complexity of decisions related to use of reproductive technologies. In some cases, this is 253 
done using simplifying heuristics (25). Some who find reproductive decisions too 254 
overwhelming choose not to choose, leaving future children to chance, rejecting PND and 255 
therefore any subsequent, potentially stressful decisions (321). Others elect to eliminate the 256 
possibility of future pregnancies altogether, as Kelly (29) found in her qualitative study of 257 
parents of children affected with various genetic conditions.  258 
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 259 
The literature provided little insight into the role of healthcare staff in providing family 260 
planning support for these parents. In those studies where it was considered (23-25, 28), it 261 
was confined to the role of metabolic physicians or genetic counsellors in offering genetic 262 
technologies and explaining them, if appropriate. There is a lack of consideration of specialist 263 
reproductive services in the published literature.  264 
 265 
A lack of access to acceptable contraception, and inconsistent or incorrect use of 266 
contraceptives, are major contributors to unplanned pregnancies (323,334). Early initiation of 267 
effective postpartum contraception including long-acting reversible methods substantially 268 
improves the odds of an inter-pregnancy interval of greater than 18 months (354,356). Access 269 
to high-quality reproductive healthcare from the point of diagnosis of the affected child is 270 
therefore particularly important. As our review has highlighted, reproductive decisions may 271 
alter over time, as parents adjust to their role or in response to the changing health status of 272 
their child (23,25). It is therefore important to recognise that decisions about whether or not 273 
to have children are not isolated events; they take place over time and need to be underpinned 274 
by a deliberative approach to contraceptive decision-making and access to effective 275 
contraceptive methods including long-acting reversible contraceptives, in order to both 276 
prevent unplanned pregnancy, and to enable planned pregnancy. The parents of younger 277 
children with genetic conditions are vulnerable to stress associated with caring and treatment 278 
management (14). However, there is a lack of literature to indicate the situation regarding 279 
contraceptive related decisions and the ways in which they impact on and contribute to wider 280 
reproductive decision-making processes.  281 
 282 
 283 
Limitations 284 
  285 
Our review has benefited from rigorous database searches and study selection processes. The 286 
grey literature searches, however, were not exhaustive., therefore some potentially relevant 287 
materials may have been missed. It could be argued that oOne limitation was a decision not 288 
to quality assess the included studies. However the role of quality assessment in scoping 289 
reviews has been debated (36,37), and in our review we were not synthesising the evidence 290 
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on the basis of its strength and quality, but rather identifying emergent themes and identifying 291 
gaps where research is lacking (387). 292 
 293 
Conclusion  294 
We found an overall paucity of research evidence on reproductive decision-making and the 295 
role of reproductive health services. The evidence base was confined to a limited number of 296 
conditions (predominantly CF). Although the studies were largely concerned with decisions 297 
about the use of reproductive technologies, these decisions were secondary to fundamental 298 
decisions about whether to have a further child. These decisions, which changed over time, 299 
centred on the reality of caring for the affected child and its implications on the family unit. 300 
There is a need to better understand what support parents need in their decision-making, how 301 
and when best to provide it, and by whom. Mothers' voices dominated the current literature, 302 
therefore subsequent research should focus more on the whole family unit.  303 
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Supplementary file 1: Search strategy in Medline and CINAHL Complete (EBSCOHost) 
TI = title words 
AB = abstract words 
MH = database subject headings 
n4 = proximity operator 
 
# Query Results 
S1 TI "family planning" OR AB "family planning" 14,206 
S2 TI ( (decid* OR decision* OR choos* OR choice* OR plan* OR inten* OR options) n4 reproduct* ) OR AB ( (decid* OR decision* OR choos* OR choice* 
OR plan* OR inten* OR options) n4 reproduct* ) 
5,387 
S3 TI ( (decid* OR decision OR choos* OR choice* OR plan* OR inten* OR options) n4 (contracept* OR "birth control") ) OR AB ( (decid* OR decision OR 
choos* OR choice* OR plan* OR inten* OR options) n4 (contracept* OR "birth control") ) 
3,778 
S4 TI ( (decid* OR decision OR choos* OR choice* OR plan* OR inten* OR options) AND (pregnan* n4 (further OR subsequent OR later)) ) OR AB 
( (decid* OR decision OR choos* OR choice* OR plan* OR inten* OR options) AND (pregnan* n4 (further OR subsequent OR later)) ) 
1,381 
S5 TI ( (decid* OR decision OR choos* OR choice* OR plan* OR inten* OR options) AND (preconceptual OR "pre fertili?ation" OR prefertili?ation OR 
PIGM OR CVS OR "antenatal diagnosis" OR FTS OR "first trimester screening" OR "noninvasive genetic testing" OR "prenatal screening" OR 
"antenatal screening") ) OR AB ( (decid* OR decision OR choos* OR choice* OR plan* OR inten* OR options) AND (preconceptual OR "pre 
fertili?ation" OR prefertili?ation OR PIGM OR CVS OR "antenatal diagnosis" OR FTS OR "first trimester screening" OR "noninvasive genetic testing" 
OR "prenatal screening" OR "antenatal screening") ) 
1,852 
S6 (MH "Family Planning+") 6,614 
S7 (MH "Contraception+") 27,895 
S8 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 51,665 
S9 TI ( Huntingdon* OR HD ) OR AB ( Huntingdon* OR HD ) 28,847 
S10 (MH "Huntington's Disease") 1,071 
S11 (MH "Huntington Disease") 9,032 
S12 S9 OR S10 OR S11 34,882 
S13 S8 AND S12 110 
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S14 TI ( PKU OR phenylketonuria OR hyperphenylalaninemia OR "PAH deficiency" OR "phenylalanine hydroxylase deficiency" OR H-PHE ) OR AB ( PKU 
OR phenylketonuria OR hyperphenylalaninemia OR "PAH deficiency" OR "phenylalanine hydroxylase deficiency" OR H-PHE ) 
6,379 
S15 (MH "Phenylketonuria+") 518 
S16 (MH "Phenylketonurias+") 6,102 
S17 S14 OR S15 OR S16 8,193 
S18 S8 AND S17 40 
S19 TI "congenital hypothyroidism" OR AB "congenital hypothyroidism" 2,767 
S20 (MH "Congenital Hypothyroidism") 3,728 
S21 S19 OR S20 4,610 
S22 S8 AND S21 3 
S23 TI sickle OR AB sickle 21,310 
S24 (MH "Anemia, Sickle Cell+") 20,605 
S25 TI "cystic fibrosis" OR AB "cystic fibrosis" 36,723 
S26 (MH "Cystic Fibrosis") 32,496 
S27 TI ( MCAD OR MCADD OR ("medium chain" AND "dehydrogenase deficiency") ) OR AB ( MCAD OR MCADD OR ("medium chain" AND 
"dehydrogenase deficiency") ) 
869 
S28 TI ( MSUD OR "maple syrup urine disease" OR "BCKD deficiency" OR "branched-chain ketoaciduria" OR ketoacidemia ) OR AB ( MSUD OR "maple 
syrup urine disease" OR "BCKD deficiency" OR "branched-chain ketoaciduria" OR ketoacidemia ) 
957 
S29 TI ( IVA OR IVE OR "isovaleric acidemia" OR "IVD deficiency" OR (isovaleric n3 deficiency) OR (isovaleryl n3 deficiency) ) OR AB ( IVA OR IVE OR 
"isovaleric acidemia" OR "IVD deficiency" OR (isovaleric n3 deficiency) OR (isovaleryl n3 deficiency) ) 
5,250 
S30 TI ( GA-1 OR GA1 OR GA-2 OR GA2 OR "glutaric acidemia" OR "glutaric aciduria" OR (glutaryl n4 deficiency) OR (glutarate n4 defect) OR 
"dicarboxcylic aminoaciduria" ) OR AB ( GA-1 OR GA1 OR GA-2 OR GA2 OR "glutaric acidemia" OR "glutaric aciduria" OR (glutaryl n4 deficiency) OR 
(glutarate n4 defect) OR "dicarboxcylic aminoaciduria" ) 
2,980 
S31 TI ( HCU OR HCY OR homocystinemia OR homocystinuria OR "CBS deficiency" OR (cystathionine n3 deficiency) ) OR AB ( HCU OR HCY OR 
homocystinemia OR homocystinuria OR "CBS deficiency" OR (cystathionine n3 deficiency) ) 
4,314 
S32 TI ( LCHAD OR LCHADD OR "trifunctional protein deficiency" ) OR AB ( LCHAD OR LCHADD OR "trifunctional protein deficiency" ) 184 
S33 TI ( "phenotype-genotype correlation" OR "genotype-phenotype correlation" ) OR AB ( "phenotype-genotype correlation" OR "genotype-phenotype 
correlation" ) 
2,709 
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S34 TI "rare genetic disorder*" OR AB "rare genetic disorder*" 1,037 
S35 TI "rare genetic condition*" OR AB "rare genetic condition*" 155 
S36 TI "rare metabolic disorder*" OR AB "rare metabolic disorder*" 209 
S37 TI "autosomal recessive disorder*" OR AB "autosomal recessive disorder*" 5,635 
S38 TI "autosomal recessive condition*" OR AB "autosomal recessive condition*" 672 
S39 TI "cinderella condition*" OR AB "cinderella condition*" 1 
S40 (MH "Maple Syrup Urine Disease") 981 
S41 S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 92,357 
S42 S8 AND S41 484 
 
 
  
19 
 
Table 1: Characteristics of included studies 
Citation Country Study aim*  and design Study population*  and sample size*   
Schultz et al.  
2014 (22) 
US To explore how having a child with SCD affects parents’ future reproductive decisions or 
acceptability of alternative family planning options  
Qualitative/Semi-structured Interview and grounded theory informed analysis 
Parents of children < 6 years diagnosed with SCD 
n=20 
Sawyer et al. 
2006 (23) 
Australia To assess the attitudes of parents of children with CF to PND and abortion, and to explore 
how attitudes and behaviours change over time  
Quantitative/Interview, repeated after 5 years 
Mothers of children 2-7 years diagnosed with CF  
n=56 at baseline 
n=43 at follow-up 
Dudding et 
al.2000  (24) 
Australia To document the reproductive choices made in a subsequent pregnancy after the birth of a 
child with CF identified by neonatal screening; and to determine which factors influence 
these decisions 
Quantitative/Interview and Statistical Analysis 
Mothers of children diagnosed with CF by neonatal 
screening between 1981-1996 
n=124  
Myring et al.  
2011 (25) 
UK To explore the reproductive decision  making in a sample of CF carriers with partners who 
are also CF carriers, and the views of male and female participants about the decision-
making process  
Qualitative/Semi- structured Interview and grounded theory informed analysis 
Parents of children diagnosed with CF 
n=19 
Henneman et al. 
2001 (26) 
Netherlands To investigate attitudes of parents of children with CF to use of PND and abortion, and their 
family planning and reproductive behaviours 
Quantitative/Postal Survey (part of a national study) 
Parents of children <16 years diagnosed with CF 
n=288 
Boardman  2014 
(27)  
UK To present an analysis of the ways in which 'experiences with disability', 'embodied 
experiences of impairment' and 'embodied experiences of illness, death and bereavement' 
emerged in families' accounts of living with, and making reproductive decisions around, 
SMA 
Qualitative/In-depth Interview and grounded theory informed analysis 
Parents of children diagnosed with SMA 
n=24 
Read et al. 2002 
(28) 
US To quantify and identify correlates of receptivity to PND, likelihood of terminating a future 
affected pregnancy, and whether measures had been taken to prevent a future affected 
pregnancy in parents of children with rare metabolic disorders 
Quantitative/Interview and Statistical Modelling 
Parents of children aged 6 months-18 years 
diagnosed with a rare metabolic disorder 
n=230 
*Study aim, Study  population, Sample size: Some studies addressed several research questions; only those pertinent to this review have been included in the table. The table only 
includes population and sample size data pertinent to the parents of affected children.   SCD = Sickle Cell Disease; CF = Cystic Fibrosis; SMA = Spinal Muscular Atrophy; PND = pre-
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